PACS GROUP INC (PACS) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:PACS • US69380Q1076

35.85 USD
-0.93 (-2.53%)
At close: Feb 4, 2026
35.85 USD
0 (0%)
After Hours: 2/4/2026, 8:04:00 PM
Fundamental Rating

3

Taking everything into account, PACS scores 3 out of 10 in our fundamental rating. PACS was compared to 102 industry peers in the Health Care Providers & Services industry. PACS may be in some trouble as it scores bad on both profitability and health. PACS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year PACS was profitable.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

  • The Return On Assets of PACS (0.99%) is comparable to the rest of the industry.
  • PACS has a better Return On Equity (6.40%) than 61.76% of its industry peers.
  • With a Return On Invested Capital value of 1.75%, PACS perfoms like the industry average, outperforming 43.14% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for PACS is below the industry average of 9.16%.
Industry RankSector Rank
ROA 0.99%
ROE 6.4%
ROIC 1.75%
ROA(3y)3.46%
ROA(5y)N/A
ROE(3y)120.58%
ROE(5y)N/A
ROIC(3y)4.48%
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 50 100 150 200

1.3 Margins

  • The Profit Margin of PACS (1.36%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of PACS has declined.
  • Looking at the Operating Margin, with a value of 3.01%, PACS is in line with its industry, outperforming 55.88% of the companies in the same industry.
  • PACS's Operating Margin has declined in the last couple of years.
  • PACS's Gross Margin of 19.38% is in line compared to the rest of the industry. PACS outperforms 41.18% of its industry peers.
  • PACS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.01%
PM (TTM) 1.36%
GM 19.38%
OM growth 3Y-25.04%
OM growth 5YN/A
PM growth 3Y-30.78%
PM growth 5YN/A
GM growth 3Y-5.21%
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

  • PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for PACS has been increased compared to 1 year ago.
  • Compared to 1 year ago, PACS has an improved debt to assets ratio.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • PACS has an Altman-Z score of 1.57. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.57, PACS perfoms like the industry average, outperforming 42.16% of the companies in the same industry.
  • A Debt/Equity ratio of 0.43 indicates that PACS is not too dependend on debt financing.
  • PACS has a Debt to Equity ratio of 0.43. This is in the better half of the industry: PACS outperforms 63.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACC0.2
WACC8.76%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that PACS may have some problems paying its short term obligations.
  • The Current ratio of PACS (0.94) is worse than 74.51% of its industry peers.
  • PACS has a Quick Ratio of 0.94. This is a bad value and indicates that PACS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.94, PACS is doing worse than 68.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.94
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M

More info and screens

7

3. Growth

3.1 Past

  • PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.86%.
  • Measured over the past 5 years, PACS shows a small growth in Earnings Per Share. The EPS has been growing by 4.97% on average per year.
  • The Revenue has grown by 31.44% in the past year. This is a very strong growth!
  • Measured over the past years, PACS shows a very strong growth in Revenue. The Revenue has been growing by 51.91% on average per year.
EPS 1Y (TTM)-50.86%
EPS 3Y4.97%
EPS 5YN/A
EPS Q2Q%4500%
Revenue 1Y (TTM)31.44%
Revenue growth 3Y51.91%
Revenue growth 5YN/A
Sales Q2Q%31.01%

3.2 Future

  • Based on estimates for the next years, PACS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.55% on average per year.
  • Based on estimates for the next years, PACS will show a quite strong growth in Revenue. The Revenue will grow by 16.94% on average per year.
EPS Next Y32.6%
EPS Next 2Y34.12%
EPS Next 3Y26.55%
EPS Next 5YN/A
Revenue Next Year35.43%
Revenue Next 2Y20.78%
Revenue Next 3Y16.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.07, the valuation of PACS can be described as expensive.
  • PACS's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 28.25. PACS is around the same levels.
  • PACS is valuated rather expensively with a Price/Forward Earnings ratio of 17.33.
  • PACS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PACS is cheaper than 67.65% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.50, PACS is valued a bit cheaper.
Industry RankSector Rank
PE 25.07
Fwd PE 17.33
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PACS is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 36.28
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PACS's earnings are expected to grow with 26.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y34.12%
EPS Next 3Y26.55%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for PACS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PACS GROUP INC

NYSE:PACS (2/4/2026, 8:04:00 PM)

After market: 35.85 0 (0%)

35.85

-0.93 (-2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-19
Earnings (Next)N/A
Inst Owners28.43%
Inst Owner Change1.63%
Ins Owners71.03%
Ins Owner Change0.52%
Market Cap5.61B
Revenue(TTM)4.09B
Net Income(TTM)55.76M
Analysts83.33
Price Target40.63 (13.33%)
Short Float %9.7%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.99%
Min EPS beat(2)8.66%
Max EPS beat(2)13.32%
EPS beat(4)2
Avg EPS beat(4)-6.8%
Min EPS beat(4)-32.29%
Max EPS beat(4)13.32%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)13.55%
Min Revenue beat(2)13.26%
Max Revenue beat(2)13.85%
Revenue beat(4)4
Avg Revenue beat(4)13.41%
Min Revenue beat(4)13.1%
Max Revenue beat(4)13.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.14%
PT rev (3m)45.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)15.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.81%
Valuation
Industry RankSector Rank
PE 25.07
Fwd PE 17.33
P/S 1.37
P/FCF N/A
P/OCF N/A
P/B 6.44
P/tB 6.99
EV/EBITDA 36.28
EPS(TTM)1.43
EY3.99%
EPS(NY)2.07
Fwd EY5.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS26.11
BVpS5.56
TBVpS5.13
PEG (NY)0.77
PEG (5Y)N/A
Graham Number13.38
Profitability
Industry RankSector Rank
ROA 0.99%
ROE 6.4%
ROCE 2.78%
ROIC 1.75%
ROICexc 1.91%
ROICexgc 1.94%
OM 3.01%
PM (TTM) 1.36%
GM 19.38%
FCFM N/A
ROA(3y)3.46%
ROA(5y)N/A
ROE(3y)120.58%
ROE(5y)N/A
ROIC(3y)4.48%
ROIC(5y)N/A
ROICexc(3y)4.61%
ROICexc(5y)N/A
ROICexgc(3y)4.74%
ROICexgc(5y)N/A
ROCE(3y)7.09%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-25.04%
OM growth 5YN/A
PM growth 3Y-30.78%
PM growth 5YN/A
GM growth 3Y-5.21%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA 2.28
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.94
Altman-Z 1.57
F-ScoreN/A
WACC8.76%
ROIC/WACC0.2
Cap/Depr(3y)147.98%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.35%
Cap/Sales(5y)N/A
Profit Quality(3y)200.6%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.86%
EPS 3Y4.97%
EPS 5YN/A
EPS Q2Q%4500%
EPS Next Y32.6%
EPS Next 2Y34.12%
EPS Next 3Y26.55%
EPS Next 5YN/A
Revenue 1Y (TTM)31.44%
Revenue growth 3Y51.91%
Revenue growth 5YN/A
Sales Q2Q%31.01%
Revenue Next Year35.43%
Revenue Next 2Y20.78%
Revenue Next 3Y16.94%
Revenue Next 5YN/A
EBIT growth 1Y-40.77%
EBIT growth 3Y13.87%
EBIT growth 5YN/A
EBIT Next Year78.74%
EBIT Next 3Y30.47%
EBIT Next 5YN/A
FCF growth 1Y1579.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y476.7%
OCF growth 3Y85.44%
OCF growth 5YN/A

PACS GROUP INC / PACS FAQ

What is the fundamental rating for PACS stock?

ChartMill assigns a fundamental rating of 3 / 10 to PACS.


What is the valuation status of PACS GROUP INC (PACS) stock?

ChartMill assigns a valuation rating of 4 / 10 to PACS GROUP INC (PACS). This can be considered as Fairly Valued.


What is the profitability of PACS stock?

PACS GROUP INC (PACS) has a profitability rating of 2 / 10.


What is the valuation of PACS GROUP INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACS GROUP INC (PACS) is 25.07 and the Price/Book (PB) ratio is 6.44.